MedTrace Logo

Clinical Investigation on the Performance and Safety of DermoRelizema Ecofoam

NCT04826471 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-02-18

Study results available
· View outcomes & findings →

Summary

The scope of this open label clinical trial is to evaluate and confirm the performance of DermoRelizema ecofoam in the improvement of the dermatitis severity, by alleviating the symptomatology. The disease severity will be clinically measured through the Investigator Global Assessment (IGA) after 28 days of treatment.

Conditions

  • Dermatitis

Interventions

DEVICE

DermoRelizema ecofoam

DermoRelizema ecofoam, class II a medical device, topical compact mousse, to be applied 2 times per day during the 42 days of study duration

Sponsors & Collaborators

  • Relife S.r.l.

    lead INDUSTRY

Principal Investigators

  • Gabriella Fabbrocini, MD · Ospedale "Federico II" Napoli

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-13
Primary Completion
2022-01-05
Completion
2022-01-05

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04826471 on ClinicalTrials.gov